Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_assertion type Assertion NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_head.
- NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_assertion description "[Pharmaceutical agents such as valproate, which counteract the effects of genetically determined reduced clusterin expression, may help to achieve neuroprotection and contribute to the prevention of dementia, especially in carriers of these CLU risk variants.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_provenance.
- NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_assertion evidence source_evidence_literature NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_provenance.
- NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_assertion SIO_000772 24806679 NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_provenance.
- NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_assertion wasDerivedFrom befree-2016 NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_provenance.
- NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_assertion wasGeneratedBy ECO_0000203 NP1180378.RAcdmXKMhLlePO-O4InxJzYmZItHJFoX5n3NG4DTpecXo130_provenance.